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Abstract: Introduction: The role of elevated homocysteine in primary and secondary Raynaud phenomenon (RP) and in 
patients with atherosclerosis has been reported controversially. In secondary RP due to connective tissue disease specific 
alterations of nailfold capillaries might be present. An association between these microvascular changes and homocysteine 
has been suggested. 
Aim: The aim of this study was to determine whether homocysteine level differs between patients with primary and 
secondary RP and to test the hypothesis that homocysteine or other cardiovascular risk factors are associated with specific 
features of microangiopathy in secondary RP. 
Patients and Methods: Eighty-one consecutive patients with RP referred for vascular assessment were studied by nailfold 
capillaroscopy. Homocysteine, C-reactive protein and cholesterol were measured and other cardiovascular risk factors and 
comorbidities assessed. 
Results: Homocysteine, C-reactive-protein and cholesterol levels did not differ between patients with primary (n=60) and 
secondary RP (n=21). Likewise, no differences in the prevalence of cardiovascular risk factors and comorbidities were 
found. In secondary RP no correlation was found between microvascular involvement and homocysteine or C-reactive 
protein. 
Conclusion: Plasma homocysteine is not different in patients with either primary or secondary RP and is therefore not a 
marker for the distinction of these diseases. The extent of microvascular involvement in secondary RP does not correlate 
with plasma homocysteine. 
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INTRODUCTION 
 Raynaud phenomenon results from pathological 
vasospastic response resulting in acral ischemia. The exact 
pathomechanism remains unclear. Homocysteine (Hcy) 
produces vascular endothelial damage and modifies 
circulating mediators of vasomotion. The effect of Hcy 
might be directly toxic to endothelial cells of the vessel 
leading to an activation of signal transduction pathways with 
production of superoxide radicals resulting in inflammation 
and apoptosis [1-8]. Superoxide radicals as well as Hcy may 
directly alter nitric oxide release in the endothelium and 
hence decrease vasodilatory capacity and promote 
vasoconstriction [1, 9-11]. Therefore a potentially relevant 
role for homocysteine in the pathogenesis of RP has been 
proposed. Different small studies reported increased levels of 
Hcy in secondary and primary RP [12-16]. Hcy may confer a 
mild risk alone, but it increases the risk of vascular disease in 
association with other cardiovascular risk factors such as 
arterial hypertension, dislipidemia and inflammation which 
all promote vascular lesions. Plasma Hcy levels > 10μmol/l  
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are considered cytotoxic and are found in 5 to 10% in the 
general population and in up to 40% of patients with 
vascular disease and cardiovascular risk factors [17]. 
Elevated levels of Hcy might be involved not only in 
atherogenesis but in the development of microvascular 
changes in rheumatic disease [18]. In contrast to primary RP, 
different diseases with secondary RP such as rheumatoid 
arthritis, systemic lupus erythematosus (SLE), systemic 
sclerosis (SSc), the antiphospholipid syndrome (APS), and 
systemic vasculitides have been associated with vascular 
inflammation, altered angiogenesis, and increased 
cardiovascular morbidity and mortality. Therefore, Hcy 
could be the common pathway of classical risk factors on 
one side, and inflammation on the other side. 
  A recent study reported that Hcy level correlates with the 
progression of microvascular changes found by nailfold 
capillaroscopy in patients with secondary RP [19]. Nailfold 
capillaroscopy has been accepted as one of the most valuable 
diagnostic and predictive tool for connective tissue disease, 
especially systemic sclerosis and CREST and specific 
microvascular changes might even precede the development 
of serological markers [20]. Reports on hyperhomocystei-
nemia in patients with secondary RP in relation to 
microvascular changes are conflicting and scarce, and the 
assessed number of patients relatively small. We therefore  
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tested the hypothesis that hcy plasma levels are associated 
with microvascular changes in secondary RP and would be 
different in patients with primary RP. The goal of the present 
study was to assess Hcy and microvascular alterations as 
well as cardiovascular risk factors in patients suffering from 
RP. 
METHODS 
Patient Selection and Study Design 
  The study was conducted from 2002 to 2005 at a tertiary 
referral centre as a prospective, non-randomised, single-
centre study. Plasma levels of cholesterol, homocysteine, C-
reactive protein, cardiovascular risk factors and 
comorbidities as well as patterns of nailfold capillaroscopy 
(NC) were assessed in patients with primary and secondary 
RP. To distinguish between primary and secondary RP we 
used the clinical criteria according to the American College 
of Rheumatology. Exclusion criteria were any history of 
liver diseases, cancer, or drugs that could interfere with Hcy. 
The patients underwent physical examination, nailfold 
capillaroscopy of all fingers and serological testing as part of 
the assessment for RP. 
  Hospital-based electronic charts were consulted to check 
follow-up to determine differentiation between primary and 
secondary RP in initially unclassified cases. 
  The local ethical committee had approved the study and 
all patients gave written informed consent. 
Cardiovascular Risk Factors 
  Arterial hypertension was defined as systolic blood 
pressure >140mmHg, and diastolic blood pressure 
>90mmHg measured in triplicate and after a resting period 
of 20 minutes; diabetes as fasting blood sugar >7mmol/l; 
hypercholesterolemia as fasting total serum cholesterol 
>5mmol/l; smoking was defined as current smoker or 
smoking cessation in the last ten years with at least ten pack 
years of smoking. 
Homocysteine, C-Reactive Protein, Cholesterol and 
Serological Markers 
  The blood samples were taken after an overnight fast 
between 8am and noon for determination of plasma levels of 
homocysteine (Hcy), C-reactive protein, cholesterol, antin-
uclear antibodies (ANA), anti-centromere antibodies (ACA), 
anti-scleroderma 70 antibodies (anti-Scl 70) and anti-
citrullinated peptide antibodies. Hcy and CRP were 
measured by using a chemiluminescence-enzymeimmuno-
assay method (Institute for Clinical Chemistry, University 
Hospital Zurich, Switzerland), (5 to 13.5μmol/l, norm<5 
mg/l), cholesterol by usual enzyme test (CHOD-PAP 
method), (norm<5mmol/l). Immunofluorescence method was 
used to measure ANA levels (norm<1:10), nephelometry 
method for anti-citrullinated peptide antibodies (<20 E/ml), 
Dot-Blot method for positive anti-scl 70 antibodies and 
fluorescence enzyme immuno assay method for ACA levels 
(norm<10 U/ml). 
Nailfold Capillaroscopy 
  Nailfold capillaroscopy (NC) had been performed as 
described [20]. We used an incident light fluorescence 
microscope (Leica, Heerbrugg, Switzerland) with a mercury 
vapor lamp (Leica, Heerbrugg, Switzerland) mounted on a 
heavy support (Foba, Zurich, Switzerland) with a 3-CCD 
video camera (DXC-930P, Sony, Tokyo, Japan) with a 
camera adaptor and sensitivity set on automatic control 
(CMA-D2, Sony), a video timer (VTG-22) and scale marker 
(IV-600; both from For-A-Company, Tokyo, Japan), a video 
monitor (Picture Monitor model PM 171T, Ikegami 
Tsushinki, Tokyo, Japan) and a Sony DVCAM 
Recorder/Player DSR- 45P. The microscope is equipped 
with 1.0/0.04, 2.5/0.08, 6.3/0.20 and 10/0.25 planar 
objectives (Leica), which allow a magnification of x24, x62, 
x165, and x240, respectively, on the monitor. 
  The nailfold of all ten fingers were examined. To 
improve the image resolution, a drop of immersion oil had 
been deposited on the nailfold bed. The following 
parameters of the nailfold capillaries were evaluated from 
the videotape: 
-  Irregular architecture defined as capillaries not in one 
row, small areas (<500μm) with missing capillaries 
next to areas with clusters of capillaries. 
-  Avascular fields defined as loss of capillaries in a 
field of at least 500μm. 
-  Dilatation of capillaries defined as arterial conduit 
side greater than 15μm and vein side greater than 
20μm. 
-  Giant capillaries defined as an apical diameter of 
greater than 50μm with or without hemorrhages. 
  Microvascular alterations were classified into “none”, 
“early”, and “active” and “late” patterns representing 
morphological features in connective tissue disease 
according to Cutolo et al. [21]. Regular architecture, giant 
capillaries, few haemorrhages, and no avascular fields 
represent the “early” pattern. Irregular architecture, frequent 
giant capillaries and/or haemorrhages are features of the 
“active” pattern that is considered highly specific for 
secondary RP. The “late” pattern representing the late stage 
of disease shows few giant capillaries, haemorrhages and in 
addition to them avascular fields. NC was performed and 
evaluated by a vascular technician and reviewed 
independently by an experienced physician. 
Statistics 
  Continuous variables were presented as means and 
standard deviation or median with interquartile ranges as 
appropriate due to skewed distribution. Categorical variables 
were expressed as percentages. Qualitative data were 
compared by the Fischer’s exact test. Quantitative data were 
compared using Student’s t test and Mann-Whitney U test, 
the Kruskal-Wallis test with Bonferroni Dunn corrections. 
The statistical software package Stat View 5.0 was used to 
analyse the data. All p values are two-sided. Differences 
were considered statistically significant if p<0.05. 
RESULTS 
Baseline and Clinical Characteristics 
  Clinical characteristics of the 81 patients (77% females) 
are shown in Table 1. Primary RP was diagnosed in 60 
(74%) patients and 21 (26%) had a secondary RP. Another 
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analysis due to different underlying diseases (two patients 
had a traumatic finger artery occlusion, two patients an 
embolic occlusion of a digital artery, two patients had been 
diagnosed with thrombangitis obliterans and four were 
unclassified). In female patients the prevalence of secondary 
(86%) and primary (73%) RP was not different. Although 
the patients with secondary RP tended to be older than the 
patients with primary RP this difference was not significant. 
Likewise, there were no significant differences for the 
presence of cardiovascular risk factors and co-morbidities 
between the two groups. There was no difference in Hcy and 
CRP between the two groups (Fig. 1). Table 2 shows the 
disease characteristics of the group with secondary RP with a 
50% prevalence of unclassifiable secondary RP, followed by 
CREST (29%) and systemic sclerosis (19%). 
 
Fig. (1). Box plots of homocystein plasma serum levels in patients 
with primary and secondary Raynaud phenomenon. 
Table  2.  Disease Characteristics of Patients with Secondary 
RP (n=21) 
 
Systemic Sclerosis, n (%)  4 (19) 
CREST, n (%)  6 (29) 
Mixed Connective tissue disease, n (%)  1 (5) 
Sjögren Syndrome, n (%)  1 (5) 
Unclassified, n (%)  14 (67) 
 
  In patients with secondary RP 90% showed positive 
ANCA serum levels. 13% patients presented high anti-
centromere antibodies, 31% with positive rheumatoid factors 
and 27% with positive anti-scleroderma-70 antibodies. 
Microvascular Patterns in Primary and Secondary 
Raynaud Phenomenon 
  As expected, in patients with primary RP only minor 
changes, mainly capillary tortuosity, of nailfold capillaries 
have been found. In contrast, there were major structural 
changes in patients with secondary RP. In 29% of patients 
giant capillaries, in 60% irregular architecture and in 38% 
haemorrhages were described (Table 3). This microvascular 
alterations translated into the definition of Cutolo et al. was 
as follows: Patients with primary RP (n=60) did not show 
signs of structural microangiopathy and were hence 
classified with “no microangiopathy”. From the 21 patients 
with secondary RP had 43% “early”, 19% “none”, 10% 
“active”, and 28% “late” pattern. 
  Median serum level of Hcy was 9.3μmol/l (IQR 7.4 to 
12.6μmol) in patients with primary and 10.2μmol/l (IQR 8.2 
to 14.7μmol) in patients with secondary RP (p=0.15). 
  There were no significant differences in Hcy levels in 
relation to microvascular patterns (Fig. 2). There was no   
 
Table 1.  Clinical Characteristics of Patients with Primary and Secondary RP 
 
   Primary RP 
n=60 
Secondary RP 
n=21  P 
Mean Age, yrs (range)  47 (14-84)  51 (21-83)  n.s 
Females, n (%)  44 (73)  18 (86)  n.s 
Mean Body-Mass Index, kg/m
2 (range)  22 (17-32)  24 (18-32)  n.s 
Hypertension, n (%)  7 (12)  5 (19)  n.s 
Diabetes mellitus, n (%)  4 (7)  1 (5)  n.s 
Hypercholesterolemia, mmol/l (SD)  5.3 (± 1.1)  4.3 (± 0.9)  n.s 
Smoking, n (%)  21 (35)  9 (43)  n.s 
Coronary artery disease, n (%)  0 (0)  1 (5)  n.s 
Cerebrovascular disease, n (%)  2 (3)  1 (5)  n.s 
Peripheral arterial disease, n (%)  4 (7)  2 (10)  n.s 
Systolic Blood Pressure, mmHg (SD)  124 (± 22)  125 (± 23)  n.s 
Diastolic Blood Pressure, mmHg (SD)  80 (±12)  80 (±10)  n.s 
Homocysteine, μmol/l (range)  10.6 (5-35)  11.5 (6-18)  n.s 
CRP, mg/l (range)  3.5 (1-10)  6.8 (0-40)  n.s Homocysteine and Secondary Raynaud Phenomenon  The Open Rheumatology Journal, 2011, Volume 5   67 
difference in C-reactive protein in primary RP (2mg/l, IQR 2 
to 3.5mg/l) and secondary RP (3mg/l, IQR 2 to 6mg/l). 
Table  3.  Nailfold Capillaroscopy in Patients with Primary 
and Secondary RP 
 
  Primary (n=60)  Secondary (n=21) 
Capillary turquosity, n (%)  35 (58)  18 (86) 
Irregular architecture, n (%)  1 (2)  12 (60) 
Giant capillaries, n (%)  0 (0)  6 (29) 
Hemorrhages, n (%)  0 (0)  8 (38) 
 
 
Fig. (2). Box plots of homocystein plasma serum levels in patients 
with Raynaud phenomenon in relation to microvascular patterns. * 
P-values refers to Kruskall Wallis test and ** to Bonferroni Dunn 
corrections (significance level <0.0001). 
Homocysteine Plasma Level and Morphology of Nailfold 
Capillaries in Secondary RP 
  Median Hcy plasma level was not different in patients 
with (10.4μmol/l, IQR 9 to 14.5μmol/l) and without 
microangiopathy (9.5μmol/l, IQR 7.5 to 12.7μmol/l, 
p=0.09). However, there were also no significant differences 
of median Hcy plasma levels when analyzed for the presence 
or absence of irregular architecture (10.4 μmol/l, IQR 8.6 to 
15.2μmol/l versus 10μmol/l IQR 7.5 to 12.6μmol/l, p=0.3) 
or for giant capillaries (16μmol/l, IQR 10.7 to 18μmol versus 
9.9μmol/l, IQR 7.7 to 12.6μmol, p=0.07), both specific 
features in connective tissue diseases [20]. No difference 
was found when microvascular changes were summarized as 
proposed by Cutolo et al. Hcy was 9.5μmol/l (IQR 7.5 to 
12.6μmol/l) in patients with “none” patterns, 10.2μmol/l 
(IQR 9.1 to 10.4μmol/l) in patients with “early” pattern, in 
patients with “active” pattern 9.1mol/l (IQR 8.5 to 
9.7mol/l), and in “late” pattern 14.1mol/l ( IQR 10 to 
16.8mol/l). 
Homocysteine Plasma Levels in Patients with Primary 
and Secondary Raynaud Phenomenon and Cardiovas-
cular Risk Factors 
  There was no difference of median Hcy level between 
patients with and without cardiovascular risk factors 
(9.8μmol/l, IQR 7.3 to 11.9μmol/l versus 10μmol/l, IQR 8.2 
to 13.2μmol/l). Hcy level was not different in patients with 
one or more cardiovascular co-morbidities (10.0 mol/l, IQR 
8.0 to 12.6μmol/l) compared to patients without (10.0μmol/l, 
IQR 8.2 to 12.6μmol/l, p=0.4). 
DISCUSSION 
  The multiple pathways in which Hcy affects vascular 
integrity and endothelial functional properties suggest a 
possible role of Hcy in RP and atherosclerosis.. 
  Primary Raynaud phenomenon and Hcy: In the 
present study no significant difference of Hcy in primary 
(10.6μmol/l) and secondary (11.5μmol/l) RP had been found. 
Levy et al. demonstrated in 20 patients with primary and 
secondary RP that plasma Hcy level was higher than in 
healthy controls [15]. Interestingly, in his study patients with 
primary RP had a higher Hcy than those with secondary RP 
(15.5μmol/l and 11.6μmol/l). However the value for 
secondary RP was almost the same in our study (11.5μmol/l) 
compared to the results of Levy et al. (11.6μmol/l). Hcy of 
15.5μmol/l found in primary RP is rather high for these 
otherwise healthy subjects and explains the significant 
difference between healthy controls and patients with RP in 
the study of Levy. Furthermore, the presences of 
cardiovascular risk factors or diseases that may cause 
elevated Hcy were not reported in the study of Levy. In two 
other studies patients with primary RP had Hcy levels of 7.8 
and 9.8μmol/l respectively, whereas in one study Hcy was 
even higher in controls (9.4μmol/l) than in primary RP 
(7.8μmol/l) [16]. These values correspond well with our 
result in primary RP (10.6μmol/l) [12, 16]. Therefore, from 
the current data including our study there is not sufficient 
evidence that in patients with primary RP Hcy is 
significantly elevated. 
  Secondary Raynaud phenomenon and Hcy: In our 
patient group microvascular changes and Hcy levels in 
secondary RP did not correlate as previously reported. 
Caramaschi et al. reported higher values of Hcy in patients 
with systemic sclerosis (11.8μmol/l) than in healthy controls. 
They found that the level of Hcy correlated to the severity of 
microangiopathy in nailfold capillaroscopy [19]. In our study 
population the number of patients with systemic sclerosis 
was rather low, whereas Caramaschi included only patients 
with systemic sclerosis. Again, the value of Hcy in the study 
of Caramaschi was similar to the value we had in our patient 
group (11.8 versus 11.5μmol/l) with secondary RP. Other 
published data on Hcy in secondary RP are in the same range 
(10.6 to 13.1μmol/l) [13, 15, 16, 22]. In the general 
population up to 10% have Hcy values of more than 
10μmol/l. The controversial results of the rather small 
studies comparing Hcy in patients with RP and healthy 
controls depend mostly on the differences in the control 
group which range from 5.9 to 10.7μmol/l. Cheng et al. 
compared Hcy levels in patients with SLE either with or 
without RP [13]. He found higher Hcy levels in SLE patients 
with RP (11.7μmol/l) but not in those without RP 
(8.3μmol/l) compared to controls (8.0μmol/l). It might be 
that in autoimmune diseases the elevation of Hcy represents 
an additional risk factor for developing vascular damage. 
Data proving this assumption are very scarce. We 
hypothesised that in patients with elevated plasma Hcy and 
RP inflammation or cardiovascular risk factors might 
promote microvascular alterations. In our study there were 
no differences of CRP or cholesterol levels between primary 68   The Open Rheumatology Journal, 2011, Volume 5  Jacomella et al. 
and secondary RP. Furthermore, pathological features of 
nailfold capillaries did not correlate with CRP or any 
cardiovascular risk factors. Despite some short comings of 
this study as small simple size, cross section data with only 
one time measurement and potential sample bias, it still adds 
to the scarce data available on this topic and rather supports 
that Hcy level are probably not of major relevance in 
Raynaud phenomenon. 
  In conclusion, we did not find any difference in Hcy 
levels in patients with primary or secondary RP. Neither Hcy 
nor cardiovascular risk factors nor comorbidities were 
associated with microvascular changes. 
  Prospective studies would be needed to further 
investigate whether Hcy is involved in the progression of 
micro- and macrovascular complications in different 
systemic diseases. 
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